LifeMD, Inc. (LFMD) Q3 2026 Earnings Call Transcript
LifeMD's gross margin widened to 88.8% in 2026Q2, but revenue fell 24.0% year-over-year to $47.3M and SG&A of $41.7M consumed nearly all of the $42.0M gross profit, leaving a $7.1M operating loss.
Price trend, volume and key moving averages
Trailing total returns as of 11/16/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 12, 2026 | -$0.11+22.2% vs -$0.14 | $45M-8.6% vs $49M |
Q3 2026 Aug 5, 2026 | -$0.16-9.8% vs -$0.15 | $47M-3.8% vs $49M |
Q2 2026 May 6, 2026 | -$0.20-42.9% vs -$0.14 | $50M+2.7% vs $49M |
Q2 2026 Mar 9, 2026 | -$0.04-300.0% vs -$0.01 | $47M+2.3% vs $46M |
LifeMD, Inc. (LFMD) Q3 2026 Earnings Call Transcript
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.1 per share a year ago.
LifeMD NASDAQ: LFMD lowered its full-year revenue and adjusted EBITDA outlook after third-quarter sales fell short of its forecast, as the virtual healthcare company cut marketing spending and took longer than expected to launch branded GLP-1 fulfillment arrangements.
Third quarter 2026 revenue of $44.6 million; adjusted EBITDA loss of approximately $0.4 million, within the Company's guidance range of negative $1 million to positive $2 million. Adjusted EBITDA improved approximately $3.1 million sequentially from an adjusted EBITDA loss of $3.5 million in the second quarter of 2026, driven primarily by a 34% sequential reduction in selling and marketing expenses and reduction of overall non-clinical expenses.

Benchmark LFMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for LifeMD, Inc. (LFMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.19 | $105.91M | -4.81 | -8.66% | -11.6% | -192.39% | 3.14% | |
| $19.73 | $4.4B | -24.17 | 59% | -6.65% | -45.81% | — | |
| $3.99 | $1.39B | -10.33 | 698.96% | -67.38% | -49.11% | — | |
| $33.34 | $6.24B | 44.81 | 13.05% | 21.12% | 14.81% | — | |
| $7.34 | $137.74M | 28.12 | 18.78% | 5.33% | 3.84% | — | |
| $8.80 | $1.59B | -10.34 | -1.54% | -6.27% | -11.63% | — |
LifeMD, Inc. (LFMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
LifeMD, Inc. (LFMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 22, 2026·SEC
May 6, 2026·SEC
Get notified when LFMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LifeMD, Inc. (LFMD) stock FAQ — growth, dividends, profitability & financials explained
LifeMD, Inc. (LFMD) reported $188.9M in revenue over the trailing twelve months. Revenue was $194.1M in fiscal year 2025. That is 25989% more than the $0.7M of fiscal year 2011.
LifeMD, Inc. (LFMD) revenue fell by 25.1% over the trailing twelve months, compared with the twelve months before.
No. LifeMD, Inc. (LFMD) reported a net loss of $21.9M over the trailing twelve months.
Yes. LifeMD, Inc. (LFMD) pays a dividend that yields 3.14% at the current price, a moderate yield.
LifeMD, Inc. (LFMD) had a return on equity (ROE) of -192.4% over the trailing twelve months. A negative ROE means the company lost money over the period.
LifeMD, Inc. (LFMD) had negative free cash flow of $16.1M over the trailing twelve months.